Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone.

Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone. Abstract Text:

OBJECTIVE: To describe the effects of an infusion of zoledronic acid in a patient with Paget disease of bone (PD) who had been treated unsuccessfully with several other bisphosphonates. METHODS: The patient's treatment history is described, and his response to various bisphosphonates, including zoledronic acid, is discussed. RESULTS: The patient was a 61-year-old man when a diagnosis of PD was made on the basis of an elevated serum alkaline phosphatase (ALP) level of 391 U/L (reference range, 45 to 135). Pagetic bone changes were noted on bone scan and x-ray examinations. Treatment with etidronate had no effect on ALP levels. This intervention was followed by 2 courses of intravenous therapy with pamidronate, which decreased ALP levels by 57% and 55% without inducing a remission. Subsequent oral treatment with alendronate and then risedronate yielded unsustained biochemical remissions of 6 months each. Most recently, therapy with an infusion of 5 mg of zoledronic acid induced a remission that is thus far 20 months in duration. With this therapy, the patient has experienced no side effects, and he has noted a decrease in bone pain. CONCLUSION: This case study shows that a patient with PD who received successive treatments with several bisphosphonates with inadequate responses or only brief remissions was more effectively treated with a single 5-mg infusion of zoledronic acid. This patient's therapeutic responses illustrate the relative efficacy of available bisphosphonates and the potential for longer-lasting remissions with zoledronic acid in patients with PD.

Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE: 2008 Jul-Aug

Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Endocrine practice : official journal of the Ameri

VOLUME: 14

Page Numbers: 607-10

Journal Abbreviation:

ISSN: 1934-2403

DAY: 28

MONTH: 08

YEAR: 2008

Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9607439

Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone.

AFFILIATION: Division of Endocrinology, Roger Williams Medical Center, Providence, RI 02908-4728, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Endocr Pract

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone Related Publications

• Anesthesia in fenestration surgery.
• Cerebral decompression.
• Consequences of unilateral hearing loss: Cortical adjustment to unilateral deprivation.
• Consequences of unilateral hearing loss: time dependent regulation of protein synthesis in auditory brainstem nuclei.
• Determination of myocardial infarction size in rats by echocardiography and tetrazolium staining: correlation, agreements, and simplifications.
• Effect of inappropriate and continuous therapy with alendronate for ten years on skeletal integrity - observations in two elderly patients.
• Exercise training prevents beta-adrenergic hyperactivity-induced myocardial hypertrophy and lesions.
• FIRE: fractal indexing with robust extensions for image databases.
• Mass spectrometric study of different isoforms of the plant toxin saporin.
• Mixed gonadal dysgenesis.
• Prevention of "risky" drinking among students at a Brazilian university.
• Response:.
• Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone.
• Volar forearm compartment syndrome following flexor digitorum profundus muscle rupture in a 3-year-old girl.
• [CRITERIA OF EVALUATION OF SULFONAMIDE BLOOD LEVELS DURING ORAL THERAPY OF DIABETES.]
• [Clinical contribution to the study of paralithiasic pancreatic damage]
• [Disorders of the gonadotropic function of the hypothalamo-hypophyseal system in the course of fibrous dysplasia of bone]
• [Experimental & clinical study of hemolysis induced by bubble oxygenators.]
• [Large inguino-scrotal bladder herniation]
• [Not Available.]
• [Physiopathologic problems of the surgical patient. Blood transfusion in pre- and postoperative management]
• [Role of the markers PAP-PSA in the diagnosis of cancer of the prostate]
• [THE USE OF THROMBELASTOGRAPHY IN THE STUDY OF DEFIBRINATION SYNDROMES DURING EXTRACORPOREAL CIRCULATION.]